Core Insights - Nexalin Technology, Inc. has launched its AI-designed virtual clinic platform, NeuroCare®, in collaboration with UC San Diego, aimed at enhancing patient access and reducing costs in brain health care [1][5] - The NeuroCare platform will facilitate remote treatment for conditions such as Alzheimer's, mood disorders, and military-related conditions, utilizing the Gen-3 HALO™ headset for neurostimulation [2][4] Group 1: Product and Technology - The NeuroCare platform integrates with Nexalin's Gen-3 HALO™ headset, providing a comprehensive ecosystem for remote monitoring and treatment of brain health issues [4] - The Gen-3 HALO™ headset is designed to deliver improved Deep Intracranial Frequency Stimulation (DIFS™) in a home setting, enhancing patient experience and treatment outcomes [4][6] Group 2: Business Model and Market Strategy - Nexalin's business model is subscription-based, promoting sustainable revenue and long-term patient engagement through remote monitoring and care continuity [2][3] - The company aims to scale its operations beyond device sales, focusing on data-driven revenue growth and long-term patient retention in global markets [4][5] Group 3: Clinical Research and Collaboration - The launch of the NeuroCare platform coincides with ongoing clinical trials at UC San Diego, where patient enrollment has begun for evaluating Nexalin's non-invasive treatment methods [1][4] - This collaboration is expected to enhance the clinical infrastructure and support the deployment of Nexalin's digital health ecosystem [1][4]

Core Viewpoint - Nexalin Technology, Inc. has launched a new AI-designed virtual clinic platform, NeuroCare®, in partnership with UC San Diego, aimed at enhancing access to neurotherapy for brain health disorders while reducing costs and stigma associated with treatment [1][5] Group 1: Product and Technology - The NeuroCare platform allows patients with conditions such as Alzheimer's, mood disorders, and military-related issues to use Nexalin's HALO headset for neurostimulation treatment at home [2][4] - The Gen-3 HALO™ headset integrates with the NeuroCare platform, providing a comprehensive ecosystem for remote physician oversight and advanced therapy delivery [4] Group 2: Business Model and Market Strategy - The NeuroCare platform operates on a subscription-based model, promoting sustainable revenue and long-term patient outcomes [2][3] - Nexalin aims to transition from device sales to long-term recurring revenue through data-driven clinical outcomes and patient retention strategies [4][5] Group 3: Clinical Research and Development - The collaboration with UC San Diego builds on ongoing clinical research, with patient enrollment already underway for trials evaluating Nexalin's non-invasive treatment methods [1][4] - The launch of the Gen-3 HALO headset is part of a broader strategy to address the global mental health epidemic through innovative neurostimulation technology [6]